Table 3

Characteristics of the longitudinal studies evaluating difference in testosterone (T) levels between subjects with or without venous thromboembolism (VTE) (upper panels) and risk for VTE as derived from available pharmacoepidemiological studies (lower panels)

Study (ref.)No. of patientsFollow-up duration (years)Age (years)Body mass indexDMSmokingUnadjusted risk of VTEAdjusted risk of VTE
Risk of VTE based on baseline T levels
Svartberg et al,51 20091350863±726.1±3.53.832.11.21 (0.62;2.44)*
Holmegard et al,52 201446732157 (48–65)26 (23–28)13641.30 (0.62;2.73)*
Mumoli et al,53 2015126264.6±14.226.7±2.8No difference
Risk of VTE based on TTh exposition in case–control studies
Baillargeon et al,54 2015Cases 7643 Controls 22 929≥ 400.92 (0.75;1.13)†0.90 (0.73;1.12)†
Martinez et al,55 2016Cases 19 215 Controls 909 53064.8±15.226.0±4.619.81.84 (1.42;2.38)†1.25 (0.94;1.66)†
  • *Highest versus lowest T quartile.

  • Exposed versus unexposed to testosterone treatment (TTh).

  • DM, diabetes mellitus.